A shadow market for unlicensed slimming medications is propelled by social media fitness personalities and vendors on messaging platforms, based on recent findings.
Investigational Treatment Gaining Popularity Via Social Media
Retatrutide, which remains in clinical trials, is being promoted by online personalities for its supposed weight-reducing effects. Followers are urged to message these profiles directly for source information, while also receiving promotional offers.
Active Commerce on Messaging Platforms
Separately, a flourishing trade exists on Telegram, where groups with numerous of members share comparison images, injection guides and claims of rapid UK delivery. Vendors promote the substance there before redirecting buyers to other platforms for purchases.
Understanding Retatrutide
This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could help patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.
Healthcare Professionals Voice Concerns
However, doctors and pharmacists have warned that the sale of what is still an unapproved drug in the United Kingdom is worrisome and could result in individuals administering substances of unknown origin.
Several experts stated the demand for the experimental drug could be linked to the increasing cost of licensed slimming products such as Mounjaro.
Regulatory Status and Implementation
Selling the unapproved drug on TikTok or Telegram is prohibited in the United Kingdom, as it is an unapproved medication that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.
Several influencers try to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and distribution can still breach pharmaceutical, advertising, and customer laws, potentially leading to penalties, legal action or imprisonment.
Service Response and Content Removal
Based on TikTok, the platform has taken down violative content and prohibited associated hashtags and search suggestions. The company said it was committed to maintaining the platform safe and allocating resources in strengthening compliance measures.
Online Marketplace Activities
Investigations also discovered communities with up to 9,000 members marketing the experimental drug using Telegram's integrated search feature, which operates like a public directory. Entering “retatrutide” immediately displays channels with thousands of users, filled with photos of slimming results, glowing reviews and step-by-step instructions for preparing or injecting at home.
Within minutes of joining one group, a vendor shared WhatsApp details, where most transactions occur. The seller sent an guidebook and guaranteed delivery within 48 hours. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about weight, medical conditions or previous experience.
Product Information and Pricing
Within these communities, messages show black plastic packages with postal service stickers, stating to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, mixed at residence with purified liquid, or ready-to-use pens usually priced at £160 for 20 milligrams. When asked how long a injector should be used, vendors give contradictory answers varying between a few weeks to “depends on your body”.
Service Oversight and Safety Actions
A spokesperson for the messaging service said it regularly monitored harmful material on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“Individuals are administering materials they cannot confirm. Even if the research behind retatrutide is sound, these online products may not include what they advertise,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But fake injections are highly dangerous. You can’t be certain what’s inside or whether the conditions they were made in was clean,” she explained.
Her team has previously encountered individuals injured by self-injection from unverified suppliers. “We understand the frustration, but purchasing from messaging apps or WhatsApp is gambling with your health,” stated Wyllie. “These materials could be impure or improperly measured.”
Producer Position
A representative from Eli Lilly stated retatrutide was in third stage research studies and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this point no one can sell [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a Lilly experimental product not yet authorized … may subject users to possibly significant medical dangers”.
